Accelerate Alzheimer’s trial decisions with integrated, proven endpoint strategies
Gain deeper and more complete visibility into cognition, function, and safety with integrated, science-led endpoints.
Discover how Clario delivered proven success in a complex Alzheimer’s disease clinical trial for a leading pharma partner.
Accelerate Alzheimer’s trial decisions with integrated, proven endpoint strategies
Gain deeper and more complete visibility into cognition, function, and safety with integrated, science-led endpoints.
Discover how Clario delivered proven success in a complex Alzheimer’s disease clinical trial for a leading pharma partner.
Leverage meaningful endpoints
Clario empowers you to confidently develop meaningful Alzheimer’s disease endpoints by combining advanced imaging, cognitive assessment, and data expertise to capture subtle changes, even in early-stage populations.
With an integrated approach, you can:
- Accurately quantify structural brain changes critical to Alzheimer’s progression
- Generate clear, clinically meaningful insights into cognitive outcomes
- Ensure consistent, high-quality data across global sites
By bringing together scientific expertise, robust data strategies, and centralized endpoint solutions, Clario helps you reduce variability, accelerate decision-making, and move forward with greater confidence in your trial outcomes.
Scientific expertise matters
An in-house science team provides the strategic foundation for Alzheimer’s disease clinical trials, ensuring complex endpoints are designed, managed, and evaluated with precision.
Clario’s deep scientific expertise and leadership help sponsors move beyond data collection to the study design and oversight essential for trial success.
In a field where therapeutic signals are often subtle, this hands-on approach helps ensure data are scientifically rigorous and support clear conclusions on efficacy and safety.
Why an integrated approach delivers better outcomes
Unlocking deeper insights by combining validated endpoints, advanced technologies, and scientific oversight into a unified approach.
Sponsors gain a more complete and reliable view of treatment effects by connecting eCOA, imaging, cardiac, and motion data in one ecosystem. Advanced analytics help teams identify trends and variability earlier, while standardized assessments reduce bias across global sites. With stronger evidence, sponsors can make more confident and timely decisions.
This empowers:
Clinically meaningful outcomes
Measure both cognition and function with integrated and co-primary endpoints.
Early-stage sensitivity
Capture subtle cognitive changes using validated neuro-psychological assessments and digital tools.
Flexible patient-centric data collection
Electronic data capture reduces burden for clinicians, patients, and caregivers through intuitive assessments, timely reminders, and remote participation.
Safety at scale
Monitor cardiac signals and adverse events continuously across global trials.
Get the insights you need to move forward with confidence
See the difference: how Clario’s integrated endpoints drove reliable data and faster decision-making in a global Alzheimer’s trial.